In vitro CD40-stimulated chronic lymphocytic leukemia (CLL) cells are resistant to cytotoxic drugs. In sharp contrast, we here show that CD40 stimulation sensitizes CLL cells to rituximabmediated cell death. This increased sensitivity is specific for anti-CD20 treatment. Rituximab-mediated death in CD40-stimulated CLL cells shows rapid kinetics (within hours), and is caspase and p53 independent, but depends on extracellular Ca 2 þ and reactive oxygen species (ROS) production. By increasing basal ROS production, CD40 stimulation sensitizes CLL cells to rituximab-mediated death. Our findings provide a rationale for combination treatment of CLL with cytotoxic drugs and anti-CD20 monoclonal antibodies.
Introduction

Chronic lymphocytic leukemia (CLL) is characterized by progressive accumulation of CD5
þ CD19 þ CD23 þ malignant B cells in blood, bone marrow and lymphoid organs. Although treatment results have improved considerably over the last decade, a curative treatment is still not available, with the possible exception of allogeneic stem cell transplantation. The incurability of CLL might be due to the interaction of CLL cells with their micro-environment, notably in proliferation centers in the lymph nodes. In these niches, CLL cells not only receive signals driving proliferation 1, 2 but also multiple signals resulting in resistance to cytotoxic drugs. 3 Indeed, there is histopathological evidence that in proliferation centers in lymph nodes CLL cells are exposed to CD40L þ T cells. 2, 4 We have previously shown that in vitro CD40 stimulation of peripheral bloodderived CLL cells can to a certain extent mimic the lymph node micro-environment and result in resistance to cytotoxic drugs. [5] [6] [7] Recently, it has been shown in a large randomized phase III trial that addition of the chimeric anti-CD20 monoclonal antibody (mAb) rituximab (R) to fludarabine and cyclophosphamide improves both progression free survival and overall survival in p53 functional, previously untreated CLL patients. 8 This is remarkable in view of the relatively low efficacy of rituximab when used as monotherapy at dosages used in the treatment of lymphoma. This poor efficacy has been explained by low CD20 expression levels of CLL cells, 9 ,10 the presence of complement inactivating molecules (CD55, CD59) on CLL cells, 11 the presence of soluble CD20 (ref. 12) , shaving and downmodulation of CD20 after rituximab treatment, 13, 14 resistance to antibody dependent cellular cytotoxicity by natural killer cells in vitro 15 andFlast but not leastF the intrinsic anti-apoptotic profile of CLL cells. 16 In this study, we show that, in sharp contrast to the induction of resistance to cytotoxic drugs, CD40 stimulation of CLL cells considerably increases sensitivity to anti-CD20-mediated cell death. Furthermore, we demonstrate that rituximab-induced cell death of CD40-stimulated CLL cells is caspase and p53 independent, and mediated by calcium-dependent reactive oxygen species (ROS) production.
Materials and methods
Patient samples
Peripheral blood was drawn from CLL patients (diagnosed according to the National Cancer Institute-Working Group guidelines). Peripheral blood mononuclear cells were isolated by Ficoll density gradient centrifugation (Pharmacia Biotech, Roosendaal, The Netherlands), and either used immediately or stored in liquid nitrogen. During all in vitro experiments, cells were maintained in culture medium: Iscove's modified Dulbecco medium (Gibco Life Technology, Paisley, FL, USA) supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 mg/ml gentamycin and 0.00036% b-mercaptoethanol. All peripheral blood mononuclear cell samples from CLL patients contained at least 90% CD5 þ /CD19 þ cells, as assessed through flow cytometry. The studies were approved by the Ethical Review Board of the Institute, and written informed consent was obtained from all participants.
Antibodies and reagents
The anti-CD20 mAb rituximab was kindly provided by Roche Nederland BV (Woerden, The Netherlands). The anti-CD20 mAb Ofatumumab was kindly provided by Genmab (Utrecht, The Netherlands). The anti-CD52 antibody Alemtuzumab (Ilex pharmaceuticals, San Antonio, TX, USA), goat-anti human (GAH) Fc-g-fragment-specific antibody (Jackson Immunoresearch Europe, Suffolk, UK), mouse anti-human IgM mAb (MH15, Sanquin, Amsterdam, The Netherlands), CD20-FITC clone B9E9 (Beckman Coulter, Paris, France) and FITCconjugated rabbit anti-active caspase 3 mAb (Becton Dickinson, San Jose, CA, USA) were all obtained commercially.
The pan-caspase inhibitor Q-VD was purchased from R&D systems (Minneapolis, MN, USA) and Z-VADfmk by Alexis Biochemicals (San Diego, CA, USA). Roscovitine, Fludarabine, Cisplatin, Indo1-AM, Propidium Iodide (PI), N-acetylcysteine (NAC), hydroxychloroquine, Triton-X 100 and ethylene glycol tetraacetic acid (EGTA) were purchased from Sigma Chemical Co. (St Louis, MO, USA). The proteasome inhibitor bortezomib was obtained from Janssen-Cilag (Tilburg, The Netherlands). BAPTA-AM was purchased from Calbiochem (Darmstadt, Germany). RNAse (DNAse free) was obtained by Roche. 2,7-Dichlorodihydrofluorescein diacetate (DCF-1), MitoTracker orange and Ionomycin were purchased from Molecular Probes, Leiden, The Netherlands.
FITC-labeled Annexin V was purchased from IQ products BV, Groningen, The Netherlands.
Flow Cytometry
To determine CD20 expression levels on CLL cells, peripheral blood mononuclear cells were stained using FITC-labeled antibodies against CD20, and mean fluorescence intensity was determined.
For intracellular staining, cells were fixed and permeabilised (eBioscience, San Diego, CA, USA), and subsequently stained with FITC-conjugated rabbit anti-active caspase 3 mAb. Samples were analyzed on the FACSCalibur flow cytometer (BD Biosciences, Breda, The Netherlands), and CellQuest software (Becton Dickinson) was used for data acquisition. Data were analyzed with FlowJo software (TreeStar, San Carlos, CA, USA).
In vitro CD40 ligand stimulation of CLL cells
Peripheral blood mononuclear cells from CLL patients (490% CD5 þ CD19 þ cells) were stimulated with CD40-ligand (CD40L)-transfected NIH3T3 (3T40L) cells, as described previously. 6 Briefly, 5 Â 10 6 CLL cells per well were added to 6-well plates coated with irradiated (30 Gy) CD40L-transfected NIH3T3 cells. Non-transfected 3T3 cells were used as negative controls. After 2 days, the CLL cells were gently removed from the fibroblast layer and used in further experiments.
Induction and analysis of apoptosis
For apoptosis induction, 3T3-or 3T40L-stimulated CLL cells were incubated with the indicated mAbs (10 mg/ml) for 24 h, as described previously. 17 Crosslinking GAH antibody (indicated as XL) (50 mg/ml) was added 30 min after the indicated mAbs. As a positive control for apoptosis induction, cells were treated with different cytotoxic drugs: fludarabine 50 mM, 25mM roscovitine, a cyclin-dependent kinase inhibitor and potent inducer of apoptosis in CLL 18, 19 or bortezomib 30 nM. The pancaspase inhibitors 20 mM Q-VD and 200 mM Z-VADfmk were added 30 min before the indicated time of addition of mAbs or roscovitine. To chelate extracellular calcium, EGTA was added at a concentration of 5 mM, 30 min before addition of mAbs. Intracellular calcium chelator BAPTA-AM was used at a concentration of 5 mM and added 30 min before addition of mAbs. The ROS scavenger NAC was used in a concentration of 50 mM and added 30 min before addition of respective mAbs.
Apoptosis was analyzed by evaluation of mitochondrial membrane potential with MitoTracker orange (Molecular probes), according to the manufacturer's recommendations or by Annexin V PI staining, as described previously. 20 The percentage apoptotic cells was calculated as follows: 100%ÀannV À /PI À (viable) cells. Owing to heterogeneous levels of basal apoptosis, data are expressed as relative cell death, which was defined as: % cell death in stimulated cellsÀ% cell death in medium control.
Fluorescence-activated cell sorting (FACS) analysis for subG1 DNA fragmentation DNA fragmentation was analyzed using flow cytometry after PI labeling of apoptotic nuclei, as described previously. 21 In brief, after apoptosis induction (as described above), cells were put on ice and subsequently centrifuged. While vortexing, cells were resuspended in 200 ml hypotonic solution containing 25 mg/ml PI, 100 mg/ml RNAse and 0.1% Triton-X 100 in 0.1% Na-citrate solution. Cells were incubated on ice for 1 h in the dark and analyzed by flow cytometry. The subG1 peak represents apoptotic cells.
Electron microscopy
In all, 5 Â 10 6 stimulated cells were washed twice in phosphatebuffered saline (to remove all fetal calf serum) and centrifuged. Pellets were fixed in Karnovsky's fixative (0.1 M cacodylate buffer, pH 7.4, containing 4% w/v formaldehyde and 2.5% w/v glutaraldehyde) and postfixed in 1% osmium tetroxide plus 0.5% uranyl acetate, and embedded in Epon Resin (Hexion Specialty Chemicals, Hoogland, The Netherlands). Ultra-thin sections were stained with uranyl acetate and lead citrate, and subsequently examined in a Philips CM10 electron microscope; images were obtained and measured with iTEM software (Soft Imaging System GmbH, Muenster, Germany). 17 Determination of intracellular ROS production ROS production was detected on FACSCalibur (BD Biosciences) using 2,7-dichlorodihydrofluorescein diacetate, as described previously. 22 Briefly, 0.2 Â 10 6 cells were incubated with rituximab (10 mg/ml) and crosslinking GAH antibody (50 mg/ml) for 1, 4 or 8 h in culture medium. In some experiments, cells were treated with RXL in the presence or absence of 50 mM NAC or 5 mM EGTA. After incubation with antibodies, cells were washed in warm (37 1C) phenolred-free Dulbecco's modified Eagle's medium. The pellet was resuspended in 100 ml Dulbecco's modified Eagle's medium with 1 mM 2,7-dichlorodihydrofluorescein diacetate and incubated for 30 min at 37 1C to allow cellular incorporation. ROS-dependent DCF-1 fluorescence in cells was analyzed by flow cytometry (FACSCalibur flow cytometer, BD biosciences).
Measurement of Ca
2 þ mobilization Ca 2 þ mobilization was measured as described previously. 23 Briefly, after stimulation on 3T3 or 3T40L fibroblasts, cells were gently removed from the fibroblast layer and resuspended in loading medium (Hank's buffered salt solution containing 1 mM Ca 2 þ and Mg 2 þ and 1% fetal calf serum) at a concentration of 1-10 Â 10 6 cells/ml, and loaded with 2 mM Indo-1 AM for 30 min at 37 1C while gently shaking. Then cells were washed and resuspended in loading medium at 1 Â 10 6 cells/ml. Calcium responses were measured on a Becton Dickinson FACS Vantage SE with UV excitation. Data were collected and displayed as the relative ratio of intensities of Indo fluorescence (Ca-bound Indo violet emission 405 nm/free Indo blue emission 485 nm) for each cell over time and analyzed with FlowJo software (TreeStar) . To analyze CD20-induced Ca 2 þ mobilization, cells were pre-incubated with rituximab (10 mg/ml) for 10 min and excess antibody was washed away before the start of the experiment. Samples (5 Â 10 5 cells per 10 min assay) were analyzed 1-2 min to obtain a baseline, followed by the addition of 50 mg/ml GAH antibody (CD20-induced Ca 2 þ mobilization) or 10 mg/ml mouse anti-human IgM mAb (MH15) to measure B-cell-receptor-induced Ca 2 þ mobilization. As a control, GAH antibody alone (50 mg/ml) was added (on non-rituximab preincubated cells). Ionomycin was used to control for intracellular loading of Indo-1 AM.
previously. 24 Data were normalized by setting the sum of all signals at 100% and expressing individual peaks relative to the 100% value.
Statistics
The Shapiro-Wilk normality test was performed to test Gaussian distribution. When there was Gaussian distribution, a two-sided paired t-test was used to analyze differences between the groups. The two-tailed Mann-Whitney U-test was used to analyze differences between two groups, and a Wilcoxon matched paired test was used to analyze differences between paired samples when there was no Gaussian distribution. P-values o0.05 were considered to be statistically significant.
Results
CD40 stimulation sensitizes CLL cells to anti-CD20-mediated death
Previous studies have shown that CD40-stimulated CLL cells are resistant to various cytotoxic drugs and CD95L. 5, 6, 25 But the sensitivity of CD40-stimulated CLL cells to CD20 antibodies is not known. Therefore, rituximab-mediated cell death of CD40-stimulated CLL cells from 17 CLL patients was tested. Patient characteristics are listed in Table 1 . In initial experiments, anti-CD52 mAbs were used for comparison. Figure 1a shows typical Annexin V PI FACS plots of rituximab-induced cell death. 26 Maximal levels of cell death were induced at a rituximab concentration of 10 mg/ml (not shown). Assessment of cell death by evaluation of mitochondrial membrane potential with MitoTracker and by Annexin V/PI staining gave similar results (data not shown).
In line with previous studies, 17, 27 rituximab and anti-CD52 mAb induced apoptosis only after crosslinking (XL) (Figures 1a and b). XL alone did not induce apoptosis ( Figure 1b) . Surprisingly, CD40-stimulated (3T40L) CLL cells were more sensitive to rituximab-mediated death than unstimulated (3T3) CLL cells ( Figure 1 , P ¼ 0.0064). This was in contrast to cell death caused by CD52XL (Figures 1a and b) , which was clearly inhibited by CD40 stimulation (P ¼ 0.0023), indicating that CD40-induced enhancement of rituximab-induced cell death is specific. To exclude that the CD40-mediated sensitization is rituximab specific, we also tested Ofatumumab, another so-called type I anti-CD20 antibody (for review see ref. 28 ). Ofatumumab also induced increased cell death in CD40-stimulated CLL cells as compared with unstimulated CLL cells ( Figure 1c ). Like rituximab, Ofatumumab only induced cell death in the presence of a crosslinking antibody (data not shown).
In agreement with our previous studies, 5, 6 CD40-stimulated CLL cells were resistant to fludarabine, roscovitine and bortezomib ( Figure 1d ). CD40-stimulated CLL cells with unmutated and mutated immunoglobulin variable heavy-chain (IGHV) genes had similar sensitivity to rituximab-mediated death (data not shown), and no differences in rituximab-induced cell death was observed between never treated and previously treated patients. Importantly, p53 dysfunctional CD40-stimulated CLL cells were also sensitive to rituximab-mediated death in vitro (Supplementary Figure 1) .
It has been shown that CD20 levels determine the in vitro susceptibility to rituximab. 11, 29 Thus, a rather trivial explanation for the increased sensitivity of CD40-stimulated CLL cells to rituximab-mediated cell death might be CD40-induced upregulation of CD20 expression levels. However, CD20 expression levels of unstimulated (3T3) and CD40-stimulated (3T40L) CLL cells did not differ (Supplementary Figure 2) .
Rituximab-mediated death in CLL is caspase independent
In line with previous studies using B cell lines, 17 inhibition of caspases with Q-VD or Z-VAD did not block rituximab-induced cell death of unstimulated (3T3) CLL cells (data not shown) or CD40-stimulated CLL cells (Figure 2a) . In contrast, roscovitineinduced apoptosis 19 was completely blocked in the presence of Q-VD or Z-VAD (Figure 2a) .
Despite the lack of a blocking effect of pan-caspase inhibitors, rituximab-induced cell death displayed three hallmarks of apoptosis. The first classical hallmark was phosphatidyl serine exposure as measured with Annexin V (Figure 2a) . Second, Figure 2 Rituximab-mediated cell death of CLL cells is caspase independent. CD40-stimulated (3T40L) CLL cells were incubated with rituximab in the presence or absence of Q-VD or Z-VAD, as described in Materials and methods. As a positive control for caspase 3 activation and apoptosis induction, 25 mM roscovitine was used in unstimulated (3T3) CLL cells. 19 Apoptosis was analyzed by Annexin V PI staining. Active caspase 3 and DNA fragmentation were measured as described in Materials and methods. 
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The third classical hallmark of apoptosis was the induction of a subG1 peak as a result of DNA fragmentation. A subG1 peak was seen both in CD40-stimulated (Figure 2d, upper panel) and unstimulated CLL cells (data not shown). Similar to its lack of effect on caspase 3 activation, Q-VD pre-treatment did not inhibit rituximab-induced DNA fragmentation, whereas roscovitine-induced DNA fragmentation was inhibited in the presence of Q-VD (Figure 2d) .
Finally, rituximab-induced cell death displayed remarkable fast kinetics. The decrease in Annexin V À /PI À cells and caspase 3 activation occurred within 1 h after addition of rituximab and XL (data not shown).
In summary, our data show that rituximab-induced cell death in CLL cells occurs within hours and is caspase independent.
Rituximab crosslinking causes strong homotypic aggregation (HA) in CD40-stimulated CLL cells
Recently, Ivanov et al. 26 described a homotypic aggregation (HA)-related cell death by type II anti-CD20 mAbs in cell lines. It has been shown that HA occurs after CD40 stimulation of normal B cells. 31 In primary CLL cells, we also observed HA upon CD40 stimulation ( Figure 3) . As expected from a type I antibody, 32 rituximab alone did not induce HA, neither in unstimulated nor in CD40-stimulated CLL cells (Figure 3 ). Crosslinked rituximab strongly increased HA in CD40-stimulated CLL cells (Figure 3 ). In contrast, crosslinking of anti-CD52 induced only weak HA in CD40-stimulated CLL cells (Figure 3) . In control experiments, XL alone did not induce HA (Figure 3 ). Blocking LFA-1 antibodies showed no effect on HA or cell death (data not shown), suggesting a b 2 -integrin-independent mechanism of HA.
No morphological signs of classical apoptosis in rituximab-treated CD40-stimulated CLL cells
To test whether RXL induced classical apoptosis in CD40-stimulated CLL cells, we performed electron microscopy (EM). RXL induced cytoplasmic vacuolization in the presence of relatively intact nuclei in CD40-stimulated CLL cells (Figure 4) . The latter has been described as the pattern characteristic for cell death induced by anti-CD20. 17, 26 In contrast to roscovitinetreated cells (Figure 4) , rituximab-treated CD40-stimulated CLL cells displayed no morphological signs of classical apoptosis, such as chromatin condensation, pyknotic nuclei, cell shrinkage, disintegration of cytoplasmic organelles and apoptotic bodies.
Rituximab-mediated death of CD40-stimulated CLL cells is Ca 2 þ and ROS dependent
It has been shown that CD20 can function as Ca 2 þ channel 23, 33, 34 and that anti-CD20-mediated cell death is Ca 2 þ dependent. 32, 35 In agreement with previous studies, 23, 34 we found that in the presence of a crosslinking antibody, rituximab induced a Ca 2 þ flux in CLL cells (Supplementary Figure 3) . The pattern was different from the Ca 2 þ flux after B-cell receptor stimulation with anti-IgM mAb (MH15) (Supplementary Figure 3) . When used alone, the XL antibody did not induce a Ca 2 þ flux (data not shown). To test whether rituximab-induced cell death was Ca Figure 6c shows the fold increase in ROS production in five individual patients after 1 h RXL. As shown in Figure 6d , this increase is blocked by EGTA, indicating dependence on extracellular calcium.
To test whether ROS have a role in rituximab-mediated cell death, CD40-stimulated CLL cells were incubated for 30 min with the ROS scavenger NAC before the addition of rituximab and XL. NAC was found to inhibit both the rituximab-induced increase in ROS production (Figure 6d ) and the rituximabinduced cell death (Figure 6e CD40 stimulation sensitizes CLL cells to rituximab-induced cell death M Jak et al scavenger Tiron, similar results were obtained (data not shown). Importantly, NAC did not inhibit roscovitine or anti-CD52-induced cell death (data not shown), indicating that effects of NAC are specific for rituximab-induced cell death. In summary, our data show that CD40 stimulation of CLL cells increases basal ROS production, which is further increased by addition of rituximab and XL. Moreover, rituximab-induced ROS generation and resulting cell death are dependent on extracellular calcium.
Recent studies from our group show synergistic effects of the ROS-inducing drug cisplatin and fludarabine as to cell death induction of CLL cells. 44 In line with this, RXL also sensitized to fludarabine-induced cell death in CD40-stimulated CLL cells (Figure 7) . Moreover, in contrast to fludarabin, cisplatin was able to induce cell death in CD40-stimulated cells (Figure 7) , and combination treatment of RXL and cisplatin induced strong cell death (Figure 7) . 
CD40 stimulation sensitizes CLL cells to rituximab-induced cell death
M Jak et al
Discussion
The major findings of our study can be summarized as follows:
(1) Although CD40 stimulation renders CLL cells resistant to various cytotoxic drugs, 5, 6 it sensitizes CLL cells to anti-CD20-mediated cell death, also in p53 dysfunctional CLL cells. (2) This increased sensitivity cannot be explained by a change in CD20 expression levels and appears not to be a feature of all mAbmediated cell death, as it is not observed with anti-CD52 treatment. (3) Rituximab-mediated death in CD40-stimulated CLL cells is caspase independent, shows rapid kinetics (within hours) and is dependent on extracellular Ca 2 þ and the production of ROS. (4) In CD40-stimulated CLL cells, RXL induces strong homotypic aggregation.
There is controversy concerning the possible mechanisms of anti-CD20-induced cell death. Although some reports indicated that cell death induced by CD20 crosslinking has features of classical apoptosis, 17, [45] [46] [47] others were unable to confirm these findings. 17, 27, 48, 49 A number of findings in our study strongly suggest that rituximab-induced cell death is a form of nonclassical apoptosis. First, although three classical hallmarks of apoptosis were observed (Annexin V exposure, caspase 3 CD40 stimulation sensitizes CLL cells to rituximab-induced cell death M Jak et al activation and DNA fragmentation), broad-spectrum caspase inhibitors did not block these features or cell death. Theoretically, this lack of inhibition by pan-caspase inhibitors might be due to inactivation of Z-VAD or Q-VD by the ROS induced by rituximab. However, incubation of pan-caspase inhibitors with oxygen radicals had no effect on the activity of these compounds (data not shown). Also, the observed caspase 3 cleavage, which could not be blocked by caspase inhibitors, might be explained as a bystander phenomenon, rather than as an initiator of cell death. This has recently also been described in the caspase-independent cell death of glioblastoma cell lines incubated with taurolidine. 50 Moreover, ongoing processing of caspase 3 in the presence of Z-VAD has been described before in B cells after B-cell receptor triggering and interestingly also after treatment with the ROS-inducing agent CCCP. 30 Second, the rapid kinetics of rituximab-induced cell death in CLL cells (within hours) is certainly not characteristic for classical apoptosis. This rapid kinetics makes it unlikely that rituximab-mediated death in CLL cells is at the level of transcriptional or translational regulation. This notion is supported by multiplex mRNA analysis: In contrast to CLL cells treated with fludarabine that showed a significant upregulation of p53-induced apoptosis-regulating genes p21 and Puma, no evidence for transcriptional regulation of apoptosis-regulating genes by rituximab was observed (Supplementary Figure 4) . Furthermore, CD20 binding in CLL cells did not have an effect on Raf-1 kinase inhibitor protein levels (data not shown), previously reported to be upregulated in NHL B cell lines after anti-CD20 treatment. 51 Third, our EM data in rituximab-treated CD40-stimulated CLL cells did not reveal classical signs of apoptosis butFin agreement with a recent report 26 Frather gross vacuolization of cytoplasm with relatively intact nuclei. In contrast to recent studies describing the involvement of autophagy in anti-CD20-mediated death of Burkitt lymphoma cell lines, 52, 53 we found no evidence for RXL-induced autophagy in CD40-stimulated CLL cells (data not shown).
CD20 has been described as Ca 2 þ channel. 33, 34, 54 Type I anti-CD20 antibodies are thought to induce direct cell death by inducing a Ca 2 þ flux (reviewed in ref. 32). Indeed, upon RXL, CLL cells showed a rapid Ca 2 þ flux preceding cell death. Rituximab-induced cell death could be blocked by EGTA but not by BAPTA-AM, in agreement with recent data showing that extracellular calcium has a pivotal role in anti-CD20-induced cell death. 52 At present, it is unclear whether it is the CD20 molecule itself that allows Ca 2 þ entry or another anion channel that opens upon CD20 binding. 36, 37 We therefore hypothesized that a rise in [Ca 2 þ ] i would induce production of ROS in CLL cells after ligation of CD20. Indeed, ROS were increased in CD40-stimulated CLL cells after RXL, whereas this was not observed in unstimulated CLL cells. Moreover, rituximab-induced ROS production and cell death were inhibited in the presence of the ROS scavenger NAC. Recently, the involvement of ROS was also described in cell death induced by anti-HLA-DR mAbs. 55 Rituximab-induced ROS production was impaired in the presence of EGTA, supporting our hypothesis that Ca 2 þ is important for rituximab-induced ROS. Zhou et al. 56 showed that CLL cells with higher basal ROS are more sensitive to 2-Methoxyestradiol, a compound that induces apoptosis via a free radical-mediated mechanism. On the basis of our data, we propose that CD40 stimulation sensitizes CLL cells to rituximab-mediated death by increasing basal ROS production, which is further increased by rituximab. ROS production after CD40 stimulation has been described before in B cells, 57 and CD40-induced ROS have critical roles in CD40-mediated B-cell regulation, for example, nuclear factor-kB signaling. 58 Our data indicate that constitutive CD40 signaling results in activation of CLL cells and increased basal ROS production.
The increased sensitivity of CD40-stimulated CLL cells to the ROS-inducing agent cisplatin 59 ( Figure 7 ) is in line with CD40-induced ROS-dependent sensitization to rituximab. Furthermore, combination treatment of RXL and fludarabine showed synergistic effects in CD40-stimulated CLL cells (Figure 7) . We hypothesize that RXL induces ROS and thereby sensitizes to fludarabine-induced cell death, correlating with earlier findings that fludarabine shows synergistic effects with cisplatin as ROSinducing agent. 44 Importantly, this increase in ROS production appears to be rituximab specific because cytotoxic drugs, such as fludarabine and roscovitine, did not induce ROS in CD40-stimulated CLL cells (unpublished data). Finally, we showed that CD40 stimulation of CLL cells induced sensitization not only to rituximab-induced cell death but also to that induced by ofatumumab (another type I anti-CD20 mAb). Whether CD40 stimulation also sensitizes to type II anti-CD20 mAbs is subject of our ongoing research.
In conclusion, this study shows that CD40 stimulation sensitizes CLL cells to rituximab-induced cell death via a Ca 2 þ -dependent increase in ROS production. As CD40 stimulation is considered to be part of the micro-environmental stimuli rendering CLL cells less sensitive to cytostatic drugs, our data provide a strong rationale for adding rituximab to * * ** * CD40 stimulation sensitizes CLL cells to rituximab-induced cell death M Jak et al chemotherapy regimens, like, for example, fludarabine and cyclophosphamide. By bypassing the anti-apoptotic machinery, 6, 7, 17 RXL is able to induce caspase-independent cell death in CD40-stimulated CLL cells that are resistant to various drugs as result of upregulation of Bcl-2 family members. 5, 6 Moreover, our findings suggest that it might be very relevant to combine rituximab with other ROS-inducing drugs like arsenic trioxide 56 or cisplatin. 59 
